DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension

NCT00353574 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
282
Enrollment
INDUSTRY
Sponsor class

Stopped Study DAR-312 did not meet primary co-endpoints

Conditions

Interventions

Sponsor

Gilead Sciences